Literature DB >> 14695475

Bcl10 activates the NF-kappaB pathway through ubiquitination of NEMO.

Honglin Zhou1, Ingrid Wertz, Karen O'Rourke, Mark Ultsch, Somasekar Seshagiri, Michael Eby, Wei Xiao, Vishva M Dixit.   

Abstract

The NF-kappaB family of transcription factors is activated in response to many stimuli, including pro-inflammatory cytokines, environmental stresses and, in the case of B and T lymphocytes, by antigenic stimulation. Bcl10 is essential for NF-kappaB activation by T- and B-cell receptors. T and B lymphocytes from Bcl10-deficient mice fail to activate NF-kappaB in response to antigen-receptor stimulation and, as a consequence, are unable to proliferate. Bcl10 overexpression is sufficient to activate NF-kappaB, a process that requires the NF-kappaB essential modulator NEMO (also known as IKK-gamma), which is the regulatory subunit of the IkappaB kinase complex. However, the cellular mechanism by which Bcl10 activates the NF-kappaB pathway remains unclear. Here we show that Bcl10 targets NEMO for lysine-63-linked ubiquitination. Notably, a mutant form of NEMO that cannot be ubiquitinated inhibited Bcl10-induced NF-kappaB activation. Paracaspase and a ubiquitin-conjugating enzyme (UBC13) were both required for Bcl10-induced NEMO ubiquitination and subsequent NF-kappaB activation. Furthermore, short interfering RNAs that reduced the expression of paracaspase and UBC13 abrogated the effects of Bcl10. Thus, the adaptor protein Bcl10 promotes activation of NF-kappaB transcription factors through paracaspase- and UBC13-dependent ubiquitination of NEMO.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14695475     DOI: 10.1038/nature02273

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  192 in total

Review 1.  Role of T cell-nuclear factor κB in transplantation.

Authors:  Luciana L Molinero; Maria-Luisa Alegre
Journal:  Transplant Rev (Orlando)       Date:  2011-11-08       Impact factor: 3.943

Review 2.  C-type lectin receptor-induced NF-κB activation in innate immune and inflammatory responses.

Authors:  Lara M Kingeter; Xin Lin
Journal:  Cell Mol Immunol       Date:  2012-01-16       Impact factor: 11.530

3.  E3Net: a system for exploring E3-mediated regulatory networks of cellular functions.

Authors:  Youngwoong Han; Hodong Lee; Jong C Park; Gwan-Su Yi
Journal:  Mol Cell Proteomics       Date:  2011-12-22       Impact factor: 5.911

Review 4.  NF-κB as a target for oncogenic viruses.

Authors:  Shao-Cong Sun; Ethel Cesarman
Journal:  Curr Top Microbiol Immunol       Date:  2011       Impact factor: 4.291

Review 5.  Signaling to NF-kappaB: regulation by ubiquitination.

Authors:  Ingrid E Wertz; Vishva M Dixit
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-03       Impact factor: 10.005

6.  NF-kappaB activation in T cells requires discrete control of IkappaB kinase alpha/beta (IKKalpha/beta) phosphorylation and IKKgamma ubiquitination by the ADAP adapter protein.

Authors:  Rupa Srivastava; Brandon J Burbach; Yoji Shimizu
Journal:  J Biol Chem       Date:  2010-02-17       Impact factor: 5.157

Review 7.  "Without Ub I am nothing": NEMO as a multifunctional player in ubiquitin-mediated control of NF-kappaB activation.

Authors:  Jérémie Gautheron; Gilles Courtois
Journal:  Cell Mol Life Sci       Date:  2010-05-26       Impact factor: 9.261

Review 8.  Oncogenic activation of NF-kappaB.

Authors:  Louis M Staudt
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-04-21       Impact factor: 10.005

9.  The CARMA3-Bcl10-MALT1 signalosome promotes angiotensin II-dependent vascular inflammation and atherogenesis.

Authors:  Linda M McAllister-Lucas; Xiaohong Jin; Shufang Gu; Katy Siu; Scott McDonnell; Jürgen Ruland; Phillip C Delekta; Matthew Van Beek; Peter C Lucas
Journal:  J Biol Chem       Date:  2010-07-05       Impact factor: 5.157

10.  Specific NEMO mutations impair CD40-mediated c-Rel activation and B cell terminal differentiation.

Authors:  Ashish Jain; Chi A Ma; Eduardo Lopez-Granados; Gary Means; William Brady; Jordan S Orange; Shuying Liu; Steven Holland; Jonathan M J Derry
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.